NRAS and neoplasm: We have previously demonstrated that the treatment of mice bearing genetically derived inducible melanoma tumors (BRAF/PTEN or NRAS/INK4a) with the CXCR1/2 antagonist (SX-682) inhibited tumor growth and increased activated CD8+ T cells, partly by reducing the intratumoral MDSCs (6).